Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant
and escalating global challenges. Its etiology is intricate and diverse, stemming from a …

Excess accumulation and aggregation of toxic soluble and insoluble amyloid-β species in
the brain are a major hallmark of Alzheimer's disease. Randomized clinical trials show …

Introduction Global estimates on numbers of persons in early stages of Alzheimer's disease
(AD), including prodromal and preclinical, are lacking, yet are needed to inform policy …

Background Development of in vivo biomarkers has shifted the diagnosis of Alzheimer's
disease (AD) from the later dementia stages of disease towards the earlier stages and has …

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …

Repetitive transcranial magnetic stimulation (rTMS) is emerging as a non-invasive
therapeutic strategy in the battle against Alzheimer's disease. Alzheimer's disease patients …

Most current Alzheimer's disease (AD) and mild cognitive disorders (MCI) studies use single
data modality to make predictions such as AD stages. The fusion of multiple data modalities …

Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …